Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent [3] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses and converting "cold" tumors to "hot" tumors [3][4] Upcoming Events - Oncolytics will host a conference call and webcast on November 12, 2024, at 8:30 a.m. ET to discuss corporate updates and financial results for Q3 2024 [1][2] Clinical Development - The company is conducting and planning combination clinical trials with pelareorep in various solid and hematological malignancies, advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]